CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Inclusion Criteria: * Patients with a cytologic diagnosis of AGC (AGC, atypical endocervical cells \[AEC\], atypical endometrial cells \[AEmC\]) or a cytologic/histologic diagnosis of AIS documented within the last 6 months who can wait at least one week after the AGC or AIS diagnosis to have an LBC specimen (i.e., ThinPrep) collected and then receive any other intervention; acceptable time frame range is 4 days prior to registration to 7 days after registration * Patients with positive HPV results who are willing to undergo a complete histologic examination of the uterus and cervix, including the cervical transformation zone, within 6 months of the AGC or AIS diagnosis (histologic examination includes a loop electrosurgical excision procedure \[LEEP\], loop excision of the transformation zone \[LETZ\], excisional cone biopsy, or hysterectomy) * Patients must have signed an approved informed consent and authorization permitting release of personal health information Exclusion Criteria: * Patients who have had a hysterectomy * History of endometrial hyperplasia or cancer of the endometrium, vagina, or cervix * Patients who have previously been treated, or are currently being treated with radiation therapy or chemotherapy for vaginal or cervical cancer * Patients who are known to be human immunodeficiency virus (HIV)-positive * Patients who are pregnant and thought to be at risk for excessive bleeding or preterm labor if a cone biopsy is performed